Biocon climbs 5% on launch of Ogivri biosimilar in US market

Ogivri is used to treat breast cancer and gastric cancer and Biocon has regulatory approval to sell it in more than 80 countries worldwide.

Shares of Biocon, the biopharmaceutical major, climbed as much as 4.8 per cent to Rs 299.70 apiece on the BSE after the company launched Trastuzumab biosimilar Ogivri in the US market. Ogivri, a biosimilar to Herceptin, has been co-developed by Biocon Biologics and Mylan and will be available in 150 mg and 420 mg strengths. 

At 09:29 am, the stock was trading over 2 per cent higher at Rs 292 as compared to 0.09 per cent decline in the S&P BSE Sensex.

Ogivri is used to treat breast cancer and gastric cancer and Biocon has regulatory approval to sell it in more